Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia

Measuring minimal residual disease (MRD) during treatment is valuable to identify acute lymphoblastic leukemia (ALL) patients who require intensified treatment to avert relapse. We performed the next-generation sequencing (NGS)-based immunoglobulin gene (Ig) clonality assay and evaluated its clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jae Wook, Kim, Yonggoo, Ahn, Ari, Lee, Jong Mi, Yoo, Jae Won, Kim, Seongkoo, Cho, Bin, Chung, Nack-Gyun, Kim, Myungshin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521036/
https://www.ncbi.nlm.nih.gov/pubmed/36185293
http://dx.doi.org/10.3389/fonc.2022.957743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521036/
https://www.ncbi.nlm.nih.gov/pubmed/36185293
http://dx.doi.org/10.3389/fonc.2022.957743

Ejemplares similares